95 Percent Reduction in Lymphedema Progression Demonstrated in PREVENT Trial

In Clinical Trials by Barbara Jacoby

From: prnewswire

Following >1,100 breast cancer survivors, PREVENT is the largest, multi-site randomized controlled trial (RCT) ever performed to study lymphedema prevention.

WHO: Professor Sheila Ridner, PhD, RN, FAAN, the Martha Rivers Ingram Professor of Nursing at Vanderbilt University School of Nursing, Principal Investigator, PREVENT trial.

WHAT: Pre-specified, interim results of the PREVENT trial demonstrate 95 percent reduction in lymphedema progression in patients monitored by L-DEX. The interim analysis followed the first 508 patients enrolled in the study through 12 months of follow up. Surveillance of women at risk for breast cancer–related lymphedema using bioimpedance spectroscopy was more effective in preventing lymphedema progression than traditional arm circumference measurement when each was combined with immediate compression therapy.

“These impressive interim results support routine clinical evaluation of breast cancer survivors in any clinical setting using the L-Dex score and early intervention,” says Dr. Ridner. “This gives hope to millions of survivors and is a practice-changer.”

The pre-specified, interim detailed results of the PREVENT trial were presented by Dr. Ridner at the 2019 Annual Meeting of the American Society of Breast Surgeons (ASBrS) and simultaneously published in Annals of Surgical Oncologyone of the leading journals in oncology and surgery.

WHEN: Ongoing – June is Cancer Survivor Month

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.